Teon treats first subject in Phase I/II solid tumor therapy trial

Teon Therapeutics has treated the first subject in its Phase I/II clinical trial of TT-816 in patients with advanced solid tumours.

The first-in-human, open-label, multiple ascending dose and dose-expansion trial is assessing the safety and efficacy of TT-816 given orally.